PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.06%
EBIT growth 1.25-1.5x RVPH's 5.85%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
7.06%
Operating income growth similar to RVPH's 7.11%. Walter Schloss would assume both share comparable operational structures.
10.36%
Net income growth above 1.5x RVPH's 5.90%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
28.30%
EPS growth above 1.5x RVPH's 7.69%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
28.30%
Diluted EPS growth above 1.5x RVPH's 7.69%. David Dodd would see if there's a robust moat protecting these shareholder gains.
24.68%
Share count expansion well above RVPH's 2.47%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
24.68%
Diluted share count expanding well above RVPH's 2.47%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
17.79%
OCF growth under 50% of RVPH's 38.83%. Michael Burry might suspect questionable revenue recognition or rising costs.
17.79%
FCF growth under 50% of RVPH's 38.83%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19298.96%
Negative 10Y OCF/share CAGR while RVPH stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-3628.66%
Negative 5Y OCF/share CAGR while RVPH is at 21.52%. Joel Greenblatt would question the firm’s operational model or cost structure.
45.61%
3Y OCF/share CAGR at 75-90% of RVPH's 53.59%. Bill Ackman would press for improvements in margin or overhead to catch up.
-15204.15%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
97.68%
5Y net income/share CAGR above 1.5x RVPH's 60.51%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
59.13%
3Y net income/share CAGR similar to RVPH's 58.01%. Walter Schloss would attribute it to shared growth factors or demand patterns.
9892.41%
Equity/share CAGR of 9892.41% while RVPH is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
293.35%
Equity/share CAGR of 293.35% while RVPH is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
201.29%
Positive short-term equity growth while RVPH is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
67.39%
Similar asset growth to RVPH's 64.40%. Walter Schloss finds parallel expansions or investment rates.
64.49%
50-75% of RVPH's 89.95%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
13.21%
We increase R&D while RVPH cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-38.56%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.